Focal structural variants revealed by whole genome sequencing disrupt the histone demethylase KDM4C in B-cell lymphomas

Autor: Cristina Lopez, Nikolai Schleussner, Stephan H. Bernhart, Kortine Kleinheinz, Stephanie Sungalee, Henrike L. Sczakiel, Helene Kretzmer, Umut H. Toprak, Selina Glaser, Rabea Wagener, Ole Ammerpohl, Susanne Bens, Maciej Giefing, Juan C. Gonzalez Sanchez, Gordana Apic, Daniel Hubschmann, Martin Janz, Markus Kreuz, Anja Mottok, Judith M. Muller, Julian Seufert, Steve Hoffmann, Jan O. Korbel, Robert B. Russell, Roland Schule, Lorenz Trumper, Wolfram Klapper, Bernhard Radlwimmer, Peter Lichter, Ralf Kuppers, Matthias Schlesner, Stephan Mathas, Reiner Siebert

Publikováno v: Haematologica, Vol 108, Iss 2 (2022)

Histone methylation-modifiers, such as EZH2 and KMT2D, are recurrently altered in B-cell lymphomas. To comprehensively describe the landscape of alterations affecting genes encoding histone methylation-modifiers in lymphomagenesis we investigated who

Externí odkaz: https://doaj.org/article/3d3b5d4cbb534e4eb3816d334f4e9a3c

Focal structural variants revealed by whole genome sequencing disrupt the histone demethylase

Autor: Cristina, Lopez, Nikolai, Schleussner, Stephan H, Bernhart, Kortine, Kleinheinz, Stephanie, Sungalee, Henrike L, Sczakiel, Helene, Kretzmer, Umut H, Toprak, Selina, Glaser, Rabea, Wagener, Ole, Ammerpohl, Susanne, Bens, Maciej, Giefing, Juan C Gonzalez, Sanchez, Gordana, Apic, Daniel, Hubschmann, Martin, Janz, Markus, Kreuz, Anja, Mottok, Judith M, Muller, Julian, Seufert, Steve, Hoffmann, Jan O, Korbel, Robert B, Russell, Roland, Schule, Lorenz, Trumper, Wolfram, Klapper, Bernhard, Radlwimmer, Peter, Lichter, Ralf, Kuppers, Matthias, Schlesner, Stephan, Mathas, Reiner, Siebert

Publikováno v: Haematologica.

Histone methylation-modifiers, like EZH2 and KMT2D, are recurrently altered in B-cell lymphomas. To comprehensively describe the landscape of alterations affecting genes encoding histone methylation-modifiers in lymphomagenesis we investigated whole

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::9674233f991554afd14bb4f5decea79d
https://pubmed.ncbi.nlm.nih.gov/35522148

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Autor: Steven Horwitz, Owen A O'Connor, Barbara Pro, Tim Illidge, Michelle Fanale, Ranjana Advani, Nancy L Bartlett, Jacob Haaber Christensen, Franck Morschhauser, Eva Domingo-Domenech, Giuseppe Rossi, Won Seog Kim, Tatyana Feldman, Anne Lennard, David Belada, Árpád Illés, Kensei Tobinai, Kunihiro Tsukasaki, Su-Peng Yeh, Andrei Shustov, Andreas Hüttmann, Kerry J Savage, Sam Yuen, Swaminathan Iyer, Pier Luigi Zinzani, Zhaowei Hua, Meredith Little, Shangbang Rao, Joseph Woolery, Thomas Manley, Lorenz Trümper, David Aboulafia, Onder Alpdogan, Kiyoshi Ando, Luca Arcaini, Luca Baldini, Naresh Bellam, Nancy Bartlett, Dina Ben Yehuda, Fabio Benedetti, Peter Borchman, Dominique Bordessoule, Pauline Brice, Javier Briones, Dolores Caballero, Angelo Michele Carella, Hung Chang, June Weon Cheong, Seok-Goo Cho, Ilseung Choi, Sylvain Choquet, Andrei Colita, Angela Giovanna Congui, Francesco D'amore, Nam Dang, Kelly Davison, Sophie de Guibert, Peter de Nully Brown, Vincent Delwail, Judit Demeter, Francesco di Raimondo, Young Rok Do, Eva Domingo, Michael Douvas, Martin Dreyling, Thomas Ernst, Keith Fay, Silvia Fernandez Ferrero, Ian Winchester Flinn, Andres Forero-Torres, Christopher Fox, Jonathan Friedberg, Noriko Fukuhara, Jose Garcia-Marco, Jorge Gayoso Cruz, Jose Gomez Codina, Remy Gressin, Andrew Grigg, Ronit Gurion, Corinne Haioun, Roman Hajek, Mathias Hanel, Kiyohiko Hatake, Robert Hensen, Netanel Horowitz, Andreas Huttmann, Arpad Illes, Kenichi Ishizawa, Miguel Islas-Ohlmayer, Eric Jacobsen, Murali Janakiram, Wojciech Jurczak, Mark Kaminski, Koji Kato, Ilya Kirgner, Ching-Yuan Kuo, Mihaela Cornelia Lazaroiu, Katell Le Du, Jong-Seok Lee, Steven LeGouill, Paul LaRosee, Itai Levi, Brian Link, Herve Maisonneuve, Dai Maruyama, Jiri Mayer, John McCarty, Pam McKay, Yosuke Minami, Heidi Mocikova, Enrica Morra, Javier Munoz, Hirokazu Nagai, Owen O'Connor, Stephen Opat, Ruth Pettengell, Antonio Pezzutto, Michael Pfreundschuh, Andrzej Pluta, PierLuigi Porcu, Hang Quach, Alessandro Rambaldi, William Renwick, Ruben Reyes, Antonia Rodriguez Izquierdo, Jia Ruan, Chiara Rusconi, Gilles Salles, Armando Santoro, Jose Sarriera, Kerry Savage, Hirohiko Shibayama, Cheolwon Suh, Anna Sureda, Mitsune Tanimoto, Masafumi Taniwaki, Herve Tilly, Marek Trneny, Lorenz Trumper, Norifumi Tsukamoto, Umberto Vitolo, Jan Walewski, Eckhart Weidmann, Martin Wilhelm, Mathias Witzens-Harig, Abdulraheem Yacoub, Kazuhito Yamamoto, Sung-Soo Yoon, Hwan Jung Yun, Jasmine Zain

Publikováno v: ECHELON-2 Study Group 2019, ' Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2) : a global, double-blind, randomised, phase 3 trial ', Lancet (London, England), vol. 393, no. 10168, pp. 229-240 . https://doi.org/10.1016/S0140-6736(18)32984-2
Horwitz, S, O'Connor, O A, Pro, B, Illidge, T, Fanale, M, Advani, R, Bartlett, N L, Christensen, J H, Morschhauser, F, Domingo-Domenech, E, Rossi, G, Kim, W S, Feldman, T, Lennard, A, Belada, D, Illés, Á, Tobinai, K, Tsukasaki, K, Yeh, S-P, Shustov, A, Hüttmann, A, Savage, K J, Yuen, S, Iyer, S, Zinzani, P L, Hua, Z, Little, M, Rao, S, Woolery, J, Manley, T, Trümper, L & ECHELON-2 Study Group 2019, ' Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2) : a global, double-blind, randomised, phase 3 trial ', Lancet, vol. 393, no. 10168, pp. 229-240 . https://doi.org/10.1016/S0140-6736(18)32984-2

BACKGROUND: Based on the encouraging activity and manageable safety profile observed in a phase 1 study, the ECHELON-2 trial was initiated to compare the efficacy and safety of brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A+CHP

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36b3b4862c5298b1ae704a6491430a8d
http://hdl.handle.net/20.500.11769/493757

Four versus six courses of a dose‐escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: Early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma

Autor: Nobert Schmitz, Marita Kloess, Marcel Reiser, Wolfgang E. Berdel, Bernd Metzner, Bernd Dorken, Michael Kneba, Lorenz Trumper, Markus Loeffler, Michael Pfreundschuh, Bertram Glass

Publikováno v: Cancer (0008543X); Jan2006, Vol. 106 Issue 1, p136-145, 0p